Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.59 |
| ▸ | HSD11B1 | P28845 | 11/20 | 0.58 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | PLD2 | O14939 | 2/20 | 0.55 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3100321 | 0.90 | PLD2 (0.66) | HSD11B1PLD2CHRM1 | |
| SCHEMBL3107130 | 0.88 | AVPR1A (0.65) | FPR2HSD11B1HRH4HRH3CHRM1 | |
| SCHEMBL3091550 | 0.88 | PLD1 (0.69) | FPR2HSD11B1HRH4PLD2PLD1 | |
| SCHEMBL3108012 | 0.85 | FPR2 (0.71) | FPR2HSD11B1HRH4OPRM1 | |
| SCHEMBL3113784 | 0.82 | HSD11B1 (0.71) | HSD11B1CHRM1OPRM1 | |
| SCHEMBL3107622 | 0.82 | HSD11B1 (0.60) | HSD11B1CHRM1 | |
| SCHEMBL3105364 | 0.80 | HSD11B1 (0.71) | FPR2HSD11B1CHRM1 | |
| SCHEMBL3109651 | 0.80 | HSD11B1 (0.60) | HSD11B1CHRM1OPRM1 | |
| SCHEMBL3103574 | 0.80 | HSD11B1 (0.70) | FPR2HSD11B1HRH4OPRM1 | |
| SCHEMBL3103017 | 0.79 | HSD11B1 (0.67) | HSD11B1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071622-B2 | 1-[1-(6-Methoxy-1H-indole-2-carbonyl)-piperidin-4-yl]-1,3-dihydro-benzoimidazol-2-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMAN-LA ROCHE INC. (US) | 2011-12-06 | — | — | US | claimed |
| US-20080139548-A1 | INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | US | claimed |
| US-8071622-B2 | 1-[1-(6-Methoxy-1H-indole-2-carbonyl)-piperidin-4-yl]-1,3-dihydro-benzoimidazol-2-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMAN-LA ROCHE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071622-B2 | 1-[1-(6-Methoxy-1H-indole-2-carbonyl)-piperidin-4-yl]-1,3-dihydro-benzoimidazol-2-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMAN-LA ROCHE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071622-B2 | 1-[1-(6-Methoxy-1H-indole-2-carbonyl)-piperidin-4-yl]-1,3-dihydro-benzoimidazol-2-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMAN-LA ROCHE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-7799923-B2 | Vasopressin receptor antagonists; (4-Benzotriazol-1-yl-piperidin-1-yl)-(5-chloro-1H-indol-2-yl)-methanone; antidepressants, anxiolytic agents; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799923-B2 | Vasopressin receptor antagonists; (4-Benzotriazol-1-yl-piperidin-1-yl)-(5-chloro-1H-indol-2-yl)-methanone; antidepressants, anxiolytic agents; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799923-B2 | Vasopressin receptor antagonists; (4-Benzotriazol-1-yl-piperidin-1-yl)-(5-chloro-1H-indol-2-yl)-methanone; antidepressants, anxiolytic agents; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2010-09-21 | — | — | US | disclosed |
| EP-2089381-B1 | INDOLES WHICH ACT AS VIA RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | disclosed |
| EP-2089381-A1 | INDOLES WHICH ACT AS VIA RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-20080269290-A1 | Indoles | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-30 | — | — | US | disclosed |
| US-20080139618-A1 | INDOLES | HOFFMAN-LA ROCHE INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139618-A1 | INDOLES | HOFFMAN-LA ROCHE INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139618-A1 | INDOLES | HOFFMAN-LA ROCHE INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139548-A1 | INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | US | disclosed |
| WO-2008068184-A1 | INDOLES WHICH ACT AS VIA RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| US-20080139548-A1 | INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | US | disclosed |
| US-20080139548-A1 | INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | US | disclosed |
| US-20080139617-A1 | INDOLES | HOFFMAN-LA ROCHE INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139617-A1 | INDOLES | HOFFMAN-LA ROCHE INC. | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139548-A1 | INDOLES | HTR1A, AVPR1A, TPH1 | FPR2 1237/4885HSD11B1 1172/4885HRH4 220/4885 |
| US-20080139617-A1 | INDOLES | HTR1A, AVPR1A, TPH1 | FPR2 1237/4885HSD11B1 1172/4885HRH4 220/4885 |
| US-20080269290-A1 | Indoles | HTR1A, AVPR1A, TPH1 | FPR2 1237/4885HSD11B1 1172/4885HRH4 220/4885 |
| US-20080139618-A1 | INDOLES | HTR1A, AVPR1A, TPH1 | FPR2 1237/4885HSD11B1 1172/4885HRH4 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.